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Data from mouse models and from human cancers have supported the idea that telomere shortening leads
to chromosomal instability and epithelial carcinogenesis. In this issue of Cancer Cell, Else et al. demonstrate
that telomere uncapping—altering a protein that protects chromosome ends without shortening telomeres—
also results in epithelial cancers.Tumorigenesis is a multistep process that
requires the accumulation of multiple
genetic changes. In human carci-
nomas—epithelial cancers—these steps
are facilitated by genomic alterations,
including aneuploidy, translocations, and
chromosomal amplifications and dele-
tions. Although the mechanisms gener-
ating these aberrant cancer genomes
remain incompletely understood, in-
creasing evidence suggests that carci-
noma development can be driven by
shortening of telomeres, the nucleopro-
tein caps that protect chromosome ends.
Telomerase—the enzyme complex that
elongates telomeres—is upregulated in
the majority of human tumors. However,
telomeres are often significantly shorter
in cancer cells, compared to neighboring
normal cells within a tissue, indicating
that telomeres shorten during the tumor
development process. When telomere
end protection is compromised, a local
DNA damage response occurs at the
chromosome end. This DNA damage
response explains replicative senes-
cence, the growth arrest that occurs in
human fibroblasts, which exhibit progres-
sive telomere shortening as these cells
divide for many population doublings in
the absence of telomerase (Palm and de
Lange, 2008). Efforts to model telomere
shortening in knockout mice deficient in
the telomerase RNA component (TERC)
showed that critical telomere shortening
led to defects in renewing tissues, due in
part to robust activation of the p53 tumor
suppressor gene in tissue progenitor cells
(Chin et al., 1999). In a setting of an
impaired p53 response, telomere short-
ening inTERC/p53+/mice led to a shift
in the tumor spectrum from lymphomas
and sarcomas, cancers typically seen in
p53+/ mice, to one dominated by carci-nomas (Artandi et al., 2000). The chromo-
somes in these carcinomas were highly
rearranged and characterized by nonre-
ciprocal translocations and focal amplifi-
cations and deletions (Maser et al.,
2007; O’Hagan et al., 2002). These chro-
mosomal aberrations strongly resembled
those in human carcinomas, suggesting
that telomere shortening may account
for many of the widespread genomic
changes see in human cancer. Indeed,
analyses of human breast cancer by
comparative genome hybridization
(CGH) revealed that gene copy number
aberrations increased substantially at the
ductal carcinoma in situ stage and that
telomeres shortened during stepwise
progression of human breast cancer
(Chin et al., 2004). Together with the
mouse model data, these findings sug-
gested that dysfunctional telomeres may
explain many chromosomal alterations in
human carcinomas.
In addition to the gradual loss of telo-
mere sequences that occurs in the
absence of telomerase, telomeres can
become dysfunctional, or uncapped,
through a different mechanism—alter-
ations in telomere-binding proteins. Telo-
meres are tracts of TTAGGG repeats and
terminate in a single-stranded overhang,
which folds back into the double-
stranded telomere to form a lariat or
t-loop structure. Telomeres are protected
by the t-loop conformation and by
shelterin, a large multisubunit protein
complex, which together prevents the
chromosome end from being recognized
as a DNA break and inhibits inappropriate
recombination. For example, loss of
TRF2, one of the proteins that bind the
double-stranded telomere sequence,
causes rapid uncapping and ligation of
chromosome ends. The single-strandedCancer Coverhang is bound by POT1, which in
turn is connected to the shelterin complex
via interaction with TPP1. Inhibition of
either POT1 or TPP1 leads to a potent
DNA damage response at telomeres
caused by disruption of this complex at
the telomere overhang (Guo et al., 2007;
Hockemeyer et al., 2007).
Now, in this issue of Cancer Cell, Else
et al. demonstrate that a mutation in a telo-
mere-binding protein leads to skin carci-
noma in mice by inducing telomere
dysfunction directly, without telomere
shortening (Else et al., 2009). The authors
study a mouse strain that harbors a hypo-
morphic mutation in TPP1. In the homozy-
gous state, this mutant—adrenocortical
dysplasia (acd)—exhibits a defect in telo-
mere capping that leads to adrenal gland
dysplasia, male germ cell loss, and skin
hyperpigmentation. In fact, the telomere
defect in TPP1acd/acd mice is sufficiently
severe that homozygous mice typically
die in utero, and few mice make it to adult-
hood. These defects are even more
severe than those seen in TERC/
mice, presumably because the preva-
lence of cells with dysfunctional telo-
meres is even greater in the acd model
than in TERC/mice. Since p53 is critical
in mediating the DNA damage response
to uncapped telomeres (Karlseder et al.,
1999), as well as to critically short telo-
meres, Else et al. asked if loss of p53
would rescue the phenotypes of the acd
mouse. They find a dramatic effect of
deleting p53, which restores viability,
enabling TPP1acd/acd mice to survive in
near Mendelian ratios. Furthermore,
hyperpigmentation and hair loss are
normalized, as is the dysplasia of the
adrenal gland in TPP1acd/acd p53/mice.
However, the phenotypic rescue by p53
loss comes at a cost. Dysfunctionalell 15, June 2, 2009 ª2009 Elsevier Inc. 455
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impaired p53 response now
render these mice highly
cancer prone, even more pre-
disposed to cancer than p53
mutant mice with intact telo-
mere function. TPP1acd/acd
p53/ mice and TPP1acd/acd
p53+/ mice developed
cancers much more rapidly
than their TPP1+/+ p53/
and TPP1+/+ p53+/ counter-
parts. Strikingly, whereas
the TPP1+/+ p53+/ mice
developed sarcomas and
lymphomas, TPP1acd/acd
p53+/ mice exhibited a shift
in the tumor spectrum toward
one dominated by carci-
nomas, including skin carci-
noma and adrenocortical
carcinoma. This shift toward
carcinomas is reminiscent of
TERC/ p53+/ mice but
also in a broad sense re-
sembles the predisposition
toward carcinomas seen in
aged humans.
Genomic analyses of the
carcinomas in TPP1acd/acd
p53+/ mice revealed the
presence of focal amplifica-
tions and deletions by CGH.
While these types of copy
number aberrations are
common in human cancers,
they are rare in mouse
tumors. Cytogenetic analysis by spectral
karyotyping (SKY) showed that carci-
nomas from TPP1acd/acd p53+/ mice
harbor complex chromosomal transloca-
tions. The genomic instability introduced
into these tumors by dysfunctional
telomeres likely leads to changes in
copy number of critical cancer genes,
which provides a selective advantage for
tumor initiation and progression. Conven-
tional mouse tumors lack this type of
instability and therefore have fairly normal
genomic profiles. From this cancer
genomics perspective, mouse cancer
models that incorporate dysfunctional
telomeres more closely resemble human
cancers.
The main findings in TPP1acd/acd p53+/
mice are strikingly similar to those in
TERC/ p53+/ mice deficient in telome-
rase. In both models, tumorigenesis was
accelerated by dysfunctional telomeres,
carcinomas emerged to dominate the
tumor spectrum, and these carcinomas
exhibited highly aberrant genomes. These
common features provide strong
evidence to support the hypothesis that
dysfunctional telomeres lead to chromo-
somal instability and carcinoma develop-
ment. Furthermore, the data provided by
Else et al. indicate that dysfunctional telo-
meres arising through two independent
means can similarly promote tumorigen-
esis (Figure 1). In settings of insufficient
telomerase, telomeres shorten gradually,
ultimately causing loss of telomere
protection at a small subset of telomeres.
How the telomere cap is altered at a criti-
cally short telomere is still not well under-
stood, but possibilities include reduced
binding of shelterin proteins and a confor-
mational change, for example, in the
t-loop structure. Alternatively, changes
in shelterin proteins themselves can lead
to telomere dysfunction in
cancer. The hypomorphic
mutation in TPP1acd/acd mice
is one such example, which
leads to a marked reduction
in TPP1 levels and to
decreased loading of POT1
onto telomeres (Guo et al.,
2007; Hockemeyer et al.,
2007).
In either case—telomere
dysfunction induced by crit-
ical shortening or telomere
dysfunction caused by
altered protein binding—
a localized DNA damage
response at the uncapped
telomere can result in ligation
of chromosome ends. These
fused chromosomes have
two centromeres and can
therefore break in subsequent
mitoses, resulting in cycles of
fusion bridge breakage that
lead to dramatic reorganiza-
tion of the cancer genome.
Amplification of specific
oncogenes and loss of tumor
suppressor genes during
these cycles of chromosomal
instability provide a strong
selective advantage for tumor
outgrowth within epithelial
tissues. These new data
showing that telomere un-
capping without shortening
can drive tumor development
provide an important new link to
chromosomal instability and suggest
experiments to determine if this specific
mechanism contributes to human carci-
nogenesis.
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Figure 1. Routes from Dysfunctional Telomeres to Carcinomas
Telomeres protect chromosome ends from being recognized as double-strand
breaks and prevent inappropriate recombination. These functions require
binding of shelterin, a complex of six proteins that protect the double-stranded
telomere and the single-stranded overhang. Dysfunctional telomeres may
arise by two independent mechanisms. In settings of insufficient telomerase,
telomeres shorten progressively, compromising end protection at a subset
of telomeres. Alternatively, interference with telomere-binding proteins can
lead to immediate uncapping of telomeres without telomere shortening. For
example, low TPP1 levels in the acd mouse results in decreased binding of
POT1 to the single-stranded overhang. In either case, the chromosome end
is recognized as DNA damage, leading to chromosomal ligation, cycles of
fusion bridge breakage, and gene amplification and deletion. These stochastic
changes in gene copy number can drive carcinoma formation in the absence of
p53 function.
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Lysophosphatidic acid (LPA; mono-acyl-
sn-glycero-3-phosphate) (Figure 1) is
a bioactive phospholipid that stimulates
the proliferation, migration, and survival of
many cell types. Its ‘‘lyso’’ prefix notwith-
standing, LPA has no membrane-perturb-
ing effects but acts as a high-affinity ligand
for specific G protein-coupled receptors.
Todate, there aresixconfirmedLPArecep-
tors (termed LPA1–6), which show a broad
tissue distribution and have overlapping
signaling properties (van Meeteren and
Moolenaar, 2007). LPA signaling has been
implicated in a great variety of biological
processes, ranging from vascular develop-
ment and neurite remodeling to inflamma-
tion and tumor progression. This multitude
of activities may seem confusing but is
consistent with the ubiquitous expression
of LPA receptors and their coupling to
a great diversity of G protein-mediated
signaling pathways, including those initi-
ated by Ras and Rho GTPases (van Meete-
ren and Moolenaar, 2007). The three
classic LPA receptors, termed LPA1–3,
belong to the so-called EDG family of
G protein-coupled receptors. The more
recently identified LPA receptors, LPA4–6,
are related to the purinergic P2Y receptorKarlseder, J., Broccoli, D., Dai, Y., Hardy, S., and
de Lange, T. (1999). Science 283, 1321–1325.
Maser, R.S., Choudhury, B., Campbell, P.J., Feng,
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Gutierrez, A., Ivanova, E., Perna, I., et al. (2007).
Nature 447, 966–971.genesis
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ipid growth factor that is produced
ia G protein-coupled receptors. In
on of ATX or LPA receptors leads to
family but are far distant from the EDG
receptors, implying that LPA receptors
have evolved from distinct ancestor genes.
LPA is produced extracellularly from
more complex lysophospholipids, particu-
larly lysophosphatidylcholine (LPC, the
most abundant phospholipid in plasma),
by a secreted (lyso)phospholipase D
named autotaxin (ATX; also known as
NPP2, nucleotide pyrophosphatase/phos-
phodiesterase 2), as illustrated in Figure 1
(van Meeteren and Moolenaar, 2007). ATX
was originally identified as an ‘‘autocrine
motility factor’’ for human melanoma cells,
but its mode of action has remained elusive
for a decade until it was discovered that
ATX is identical to plasma lysophospholi-
pase D, converting LPC to LPA. ATX is
widely expressed, with highest mRNA
levels detected in brain, lymph nodes,
kidney, and testis; it is found overex-
pressed in various cancers. Gene targeting
studies in mice indicate that ATX (encoded
byEnpp2) is essential for vasculardevelop-
ment, an unexpected finding given that
none of the previous LPA receptor knock-
outs has hinted at a role for LPA in vasculo-
genesis (van Meeteren and Moolenaar,
2007).
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invasive and metastatic mammary
Given its growth factor-like activities, it
is not surprising that LPA has long been
implicated in cancer. The oncogenic
potential of the ATX-LPA receptor axis
has become evident from studies in
nude mice. In xenografted NIH 3T3 cells,
overexpressed ATX cooperates with acti-
vated Ras to promote tumor aggressive-
ness and metastasis (Nam et al., 2000).
Overexpression of LPA1 in MDA-MB-231
breast carcinoma cells enhances tumor
growth and promotes metastasis to
bone (Boucharaba et al., 2004), whereas
overexpression of LPA1, LPA2, and LPA4
(but not LPA3) in embryonic fibroblasts
induces cell transformation and tumor
formation in conjunction with MYC and
TBX2 (Taghavi et al., 2008). Those studies
also indicate that distinct oncogenic
events must collaborate with ATX-LPA
signaling to induce tumor formation.
Of the EDG family LPA receptors, LPA2
provides the strongest case for a causal
link to cancer. Not only is LPA2 found
overexpressed in various common can-
cers, including ovarian, colon, gastric,
and invasive ductal breast carcinoma
(Kitayama et al., 2004), but a recent study
by Lin et al. (2009) demonstrates that
ell 15, June 2, 2009 ª2009 Elsevier Inc. 457
